Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine

NCT00584948 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT00584948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00584948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine
Lead sponsor
University of California, Davis
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2007
Completion date
September 30, 2012
Enrollment
94 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x premutation carriers, fragile x-associated tremor/ataxia syndrome